Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.
Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. We believe that immunosuppression-induced pneumonitis in a lung allograft is a serious dilemma for lung transplant physicians
McWilliams
Tanya J
TJ
Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Australia.
Levvey
Bronwyn J
BJ
Russell
Prudence A
PA
Milne
David G
DG
Snell
Greg I
GI
D000328:Adult; D016041:Heart-Lung Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D016040:Lung Transplantation; D008297:Male; D020123:Sirolimus / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D020123:Sirolimus